17:34 , Oct 15, 2018 |  BC Extra  |  Company News

New CEO Forster eyes capital raise for F-star

Immuno-oncology company F-star Biotechnology Ltd. (Cambridge, U.K.) named Eliot Forster as CEO, replacing John Haurum. Forster was CEO of Oxford-based TCR biologics play Immunocore Ltd. (Abingdon, U.K.), which he left in February. Since becoming CEO...
22:01 , Nov 16, 2017 |  BC Extra  |  Financial News

Protein misfolding play Orphazyme prices IPO

Protein misfolding company Orphazyme A/S (CSE:ORPHA TEMP) was unchanged on Thursday after it debuted on NASDAQ Copenhagen, raising DKK 600 million ($94.1 million) in an IPO through the sale of 7.5 million shares at DKK...
21:46 , Mar 10, 2017 |  BC Extra  |  Financial News

Protein misfolding company Orphazyme adds €14M to series B

Orphazyme ApS (Copenhagen, Denmark) added €14 million ($14.9 million) in the second and final close of its series B round, bringing the round's total to €34 million. New investors LSP and the ALS Investment Fund...
20:56 , Mar 10, 2017 |  BC Week In Review  |  Financial News

Orphazyme completes venture financing

On March 8, metabolic and neurological disease company Orphazyme ApS (Copenhagen, Denmark) raised €14 million ($14.9 million) in an extension of a series B round. New investors LSP and the ALS Investment Fund and existing...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Financial News

Hansa Medical AB proposes private placement

Hansa Medical AB (SSE:HMED), Lund, Sweden  Business: Transplant  Date announced: 2016-10-20  Type: Private placement  To be raised: Up to SEK185 million ($20.8 million)  Shares: 2.6 million  Price: SEK70  Shares outstanding prior: 32.4 million  Investors: HBM...
07:00 , Jun 1, 2015 |  BC Week In Review  |  Financial News

i-Optics completes venture financing

i-Optics Corp. , The Hague, the Netherlands   Business: Diagnostic   Date completed: 2015-05-22   Type: Venture financing   Raised: EUR13.7 million ($15.6 million)   Investors: Aescap Venture Management; HBM Partners; De Hoge Dennen; NIBC;...
07:00 , Mar 30, 2015 |  BioCentury  |  Finance

Poland backing innovators

The Polish government is backing the country's first life sciences VC to help build innovative life science companies in a country known for its services-oriented healthcare sector. While the capital and infrastructure are available, one...
02:03 , Feb 14, 2015 |  BC Extra  |  Company News

Intrexon acquires mucosal therapeutics play ActoGeniX

Synthetic biology company Intrexon Corp. (NYSE:XON) will acquire ActoGeniX N.V. (Zwijnaarde, Belgium) for $60 million. Intrexon will gain ActoGeniX's TopAct platform, an oral delivery technology based on living, non-pathogenic microorganisms, and a pipeline including two...
08:00 , Jan 19, 2015 |  BC Week In Review  |  Financial News

Orphazyme completes venture financing

Orphazyme ApS , Copenhagen, Denmark   Business: Endocrine/Metabolic   Date completed: 2015-01-09   Type: Venture financing   Raised: EUR20 million ($23.6 million)   Investors: Kurma Partners; Idinvest Partners; Novo A/S ; Sunstone; Aescap Venture Management...
02:46 , Nov 5, 2014 |  BC Extra  |  Company News

After BMS deal, F-star launches second newco

F-star Biotechnology Ltd. (Cambridge, U.K.) launched newco F-star Beta Ltd. (Cambridge, U.K.) and granted it licenses to develop antibody fragments and bispecific antibodies against certain oncology and immuno-oncology targets. F-star Biotechnology is eligible for milestones...